Biotech firm Angitia Biopharmaceuticals has snagged $46 million in a Series B extension round led by Morningside Ventures, according to a company announcement on October 19.
Morningside, founded in 1986 by Hong Kong property tycoon Ronnie Chan Chi-chung’s family, makes venture capital and private equity investments across North America, Europe, and Asia Pacific.
The round saw the participation of biopharma-focused investors including 3H Health Investment, OrbiMed Healthcare Fund Management, and Elikon Venture. Other state-affiliated investors joining the round include Oriza Seed, the early-stage equity investment platform of Oriza Holdings; and Legend Capital, the fund management arm of Legend Holdings.
The extended Series B round, which will be used to accelerate the development pipeline of the firm’s drug candidates including AGA111, AGA2115 and AGA2118, has brought the firm’s total capital raised to $170 million, per the announcement.
Founded in 2018, the firm engages in discovering and developing therapeutics to address the unmet medical needs of serious musculoskeletal diseases. The firm has operations in Guangzhou and Woodland Hills, California. Previously, the firm bagged $70 million in a Series B funding round led by Morningside Ventures in October 2021 after its Series A funding in 2020.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing all prominent venture capital transactions in the Greater China region from October 16 – 22, 2023.
